Market Research

This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, fundamental market dynamics, and key player strategies.

Growing applications of bioinformatics across industries, increasing public-private sector funding for bioinformatics services, and the shortage of skilled bioinformatics professionals (leading to increased outsourcing of bioinformatics projects) are the major factors that are expected to drive the growth of the bioinformatics services market during the forecast period.

What the Market Looks Like?

[238 Pages Report] The bioinformatics services market is projected to reach USD 5.3 Billion by 2026 from USD 2.5 Billion in 2021, at a CAGR of 15.8% during the forecast period. Asia Pacific market is expected to grow at the highest CAGR during the forecast period.

COVID-19 Impact on the global Bioinformatics Services Market

Bioinformatics services have always had huge potential when it comes to providing essential support to many areas of scientific research. The COVID-19 pandemic was a real-life test for bioinformatics. One of the major focus areas for every country during the COVID-19 pandemic has been to study and understand how to halt the progress of the virus. Decoding the genome of the novel coronavirus was a crucial step in developing vaccines and for better understanding the mechanism of the virus and how it functions in the human body.

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=75889439

What are Key Trends in the Market?

The growth of the bioinformatics services market is primarily influenced by the following factors:

• Growing applications of bioinformatics in various industries
• Increasing public-private sector funding for bioinformatics services
• Shortage of skilled bioinformatics professionals leading to increased outsourcing of bioinformatics projects
• Increasing pharmaceutical and biotech R&D expenditure
• In-house development of bioinformatics solutions and publicly available bioinformatics tools

The bioinformatics services market covers five key geographies—North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. In 2020, Asia Pacific region offered significant opportunities for the growth of the bioinformatics services market. The market growth in Asia Pacific can be attributed to the increasing incidence of genetic diseases, rising number of bioinformatics-based research studies, and growing demand for bioinformatics services from various end users.

Request for sample pages  @  https://www.marketsandmarkets.com/requestsampleNew.asp?id=75889439

According to the new market research report ”Transplant Diagnostics Market by Technology (PCR, NGS, Sanger Sequencing), Product (Instrument, Reagent, Software), Application (HLA, Blood Profile, Pathogen Detection), Type (Heart, Kidney, Liver, Bone Marrow), End User (Hospital) – Global Forecast to 2025“, published by MarketsandMarkets™, transplant diagnostics market is expected to reach USD 5.5 billion by 2025 from USD 3.6 billion in 2019, at a CAGR of 7.2%.

Major Growth Drivers:

The demand for transplant diagnostic products is expected to grow mainly due to factors such as the increasing public-private funding for target research activities, the growing burden of infectious diseases, the increasing number of transplant procedures, and technological advancements in the field of transplant diagnostics.

Expected Revenue Growth:

[227 Pages Report] The transplant diagnostics market is expected to reach USD 5.5 billion by 2025 from USD 3.6 billion in 2019, at a CAGR of 7.2%.

An analysis of the market developments between 2016 and 2019 revealed that product launches & enhancements, partnerships, agreements, and acquisitions were adopted by market players to strengthen their product portfolios and maintain a competitive position in the market. Product launches were the most widely adopted growth strategies.

Download PDF Brochure:   https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=2531061  

The molecular assay technologies segment accounted for the largest share of the transplant diagnostics market, by technology, in 2019

The market, by technology, is segmented into molecular and non-molecular assay technologies. In 2019, the molecular assay technologies segment accounted for the largest share of the market. The large share of this segment can be attributed to the benefits offered by molecular assays such as low turnaround time, high procedural efficacy, the study of multiple samples, and real-time sample analysis.

North America accounted for the largest share of the market in 2019

North America is a well-established market for medical devices. The presence of a highly developed healthcare system, high adoption of innovative transplant diagnostic technologies among medical professionals, the large volume of organ transplantation procedures performed in the region, and technological advancements in the field of transplant diagnostics are the major factors driving the market in North America.

Request for sample pages :   https://www.marketsandmarkets.com/requestsampleNew.asp?id=2531061  

Key Market Players

Some of the players in the transplant diagnostics market are Bio-Rad Laboratories, Inc. (US), Thermo Fisher Scientific Inc. (US), F. Hoffman-La Roche Ltd. (Switzerland), QIAGEN N.V. (Netherlands), bioMérieux SA (France), Immucor, Inc. (US), Becton, Dickinson and Company (US), Merck KGaA (Germany), and Hologic, Inc. (US).

The increasing adoption of telehealth and robotics surgery due to COVID-19 and the rising adoption of 5G-enabled wearable medical devices for real-time remote patient monitoring are key factors driving the growth of this market. The ability of 5G technology to transmit large patient data files quickly, advancements in telecommunication, and the availability of low-cost sensors are other major factors that are driving the growth of this market. However, the high cost of deployment of the 5G network is expected to restrain the growth of this market.

What the Market Looks Like?

The 5G in healthcare market is valued at an estimated USD 215 million in 2021 and is projected to reach USD 3,667 million by 2026, at a CAGR of 76.3% during the forecast period. The global 5G in healthcare market is segmented into five major regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa.

5G stands for the fifth generation of mobile communication technology. With each generation’s new technology and standards, there have been improvements in transmission speed and network capacity. 5G represents a big leap in cellular technology and in healthcare by providing essential levels of connectivity to enable a new health ecosystem, one that can meet the needs of patients and providers accurately, efficiently, cost-effectively, conveniently, and at a substantial scale.

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=248695375

COVID-19 Impact on the 5G in healthcare Market

COVID-19 is an infectious disease caused by the most recently discovered novel coronavirus. Largely unknown before the outbreak began in Wuhan (China) in December 2019, COVID-19 has moved from a regional crisis to a global pandemic in just a matter of a few weeks. The World Health Organization (WHO) declared COVID-19 as a pandemic on March 11, 2020. Traditional technologies in the medical field have failed to control this pandemic. Scholars, policymakers, and practitioners are searching for new technologies to control the outbreak.

What are Key Trends in the Market?

The growth of the 5G in healthcare market is primarily influenced by the following factors:

• Increasing adoption of telehealth and robotics surgery due to COVID-19
• Rising adoption of 5G-enabled wearable medical devices for real-time remote patient monitoring
• Ability of 5G technology to transmit large patient data files quickly
• Advancements in telecommunication
• Availability of low-cost sensors
• High cost of deployment of the 5G network

Based on component, the 5G in healthcare market is segmented into hardware, services, and connectivity. The hardware segment accounted for the largest share of the 5G in healthcare market in 2020. This segment is projected to reach USD 1,871.7 million by 2026, at a CAGR of 76.0% during the forecast period. The large share of this segment can primarily be attributed to the need for frequent upgradation or replacement to make optimal use of the latest software available in the market.

Read more about 5G in healthcare market

@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=248695375

Bioinformatics is the application of computer technology for the management and analysis of biological data. It includes storage, analysis, and dissemination of biological data. Bioinformatics uses computer programs for a variety of applications, including determining gene & protein functions, establishing evolutionary relationships, and predicting the three-dimensional shapes of proteins.

What the Market Looks Like?

MarketsandMarkets forecasts the global bioinformatics market is projected to reach USD 21.8 billion by 2026 from USD 10.7 billion in 2021, at a CAGR of 15.2% during the forecast period. North America dominated the bioinformatics market, with a share of 45.0% in 2020, followed by Europe and Asia Pacific.

COVID-19 Impact on the Bioinformatics Market

Bioinformatics has always had huge potential when it comes to providing essential support to many areas of scientific research. The COVID-19 pandemic was a real-life test for bioinformatics. One of the major focus areas for every country during the COVID-19 pandemic has been to study and understand how to halt the progress of the virus. Next-generation sequencing is the fundamental method for investigating SARS-CoV-2 genomes, which offers basic information about the virus. Bioinformatics pipelines and biological & host-virus interaction databases are the critical tools for calculating such data and furthering comprehension of SARS-CoV-2.

Many government bodies and private organizations across the globe are increasingly investing in the field of bioinformatics. These investments have largely resulted in data and technological advancements in bioinformatics services, which, in turn, have improved the quality of these services. 

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=39

What are Key Trends in the Market?

The growth of the Bioinformatics Market is primarily influenced by the following factors:

• Increasing public-private sector funding for bioinformatics
• Increasing demand for personalized medicine
• Increasing pharmaceutical and biotechnology R&D expenditure
• Decreasing costs of genome sequencing

The rapid advancements in next-generation sequencing (NGS) technologies have generated a large volume of biological data, and the growth of this data volume is increasing with the growing adoption of NGS. Data analysis is necessary, as a lot of information is still unexplored in genome analysis. Hence, data that remains after bioinformatics analysis carries huge importance and can be reused. The current solutions do not adequately solve the challenges of data management in bioinformatics.

Read more about Bioinformatics Market
@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=39

Market growth is driven by the global prevalence of infectious diseases & onset of COVID-19 and the growing awareness for early disease diagnosis, shift in focus from centralized laboratories to decentralized POC testing and rising technological advancements.

[263 Pages Report] The global infectious disease diagnostics market size is projected to reach USD 39.8 billion by 2026 from USD 28.1 billion in 2021, at a CAGR of 7.2%.

This study involved four major activities in estimating the current size of the infectious disease diagnostics market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research.

Market Dynamics

• Global prevalence of infectious diseases and onset of COVID-19
• Rising focus on R&D and funding in infectious disease diagnostics
• Growing awareness for early disease diagnosis in developing countries
• Rising technological advancements in infectious disease diagnostics
• Shift in focus from centralized laboratories to decentralized POC testing

COVID-19 Impact on Global Infectious Disease Diagnostics Market

COVID-19 is an infectious disease caused by the most recently discovered novel coronavirus. Largely unknown before the outbreak began in Wuhan (CHINA) in December 2019, COVID-19 moved from a regional crisis to a global pandemic in just a matter of a few weeks. The COVID-19 pandemic negatively affected the overall sales of most of the companies but had an positive impact on the infectious disease diagnostics market because of the use of infectious disease diagnostic methods for COVID-19 testing. Lockdowns resulting from the COVID-19 pandemic caused people to delay undergoing health checkups, thus affecting the number of tests being performed and sales of reagents.

Download PDF Brochure @  https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=116764589

Based on product & service, the infectious disease diagnostics market is segmented into reagents, kits, and consumables; instruments; and software & services. In 2020, the reagents, kits, and consumables segment accounted for the largest share of this market. The frequent purchase of these products due to their recurrent usage drives the market growth of this segment.

The infectious disease diagnostics market is segmented into immunodiagnostics, polymerase chain reaction (PCR), clinical microbiology, isothermal nucleic acid amplification technology (INAAT), DNA sequencing & NGS, DNA microarrays, and other technologies. In 2020, the immunodiagnostics segment accounted for the largest share. This can be attributed to the increasing use of immunoassays in COVID-19 testing, POC infectious disease testing, the development of novel immunodiagnostic tests, and the rising trend of automation.

The geographical regions mapped in the report are:1. North America2. Europe3. Asia-Pacific4. Latin America5. Middle East & Africa

The global infectious disease diagnostics market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America accounted for the largest share of the global infectious disease diagnostics market. The North American infectious disease diagnostics market’s growth can be attributed to the highly developed healthcare system in the US and Canada, the presence of many leading national clinical laboratories, and the easy accessibility to technologically advanced instruments.

Request for sample pages @  https://www.marketsandmarkets.com/requestsampleNew.asp?id=116764589

Some key players mentioned in the research report are:

• Abbott Laboratories (US)
• Roche Diagnostics Ltd. (Switzerland)
• bioMérieux SA (France)
• Thermo Fisher Scientific Inc. (US)
• Danaher Corporation (US)

  Market growth is driven by the global prevalence of infectious diseases & onset of COVID-19 and the growing awareness for early disease diagnosis, shift in focus from centralized laboratories to decentralized POC testing and rising technological advancements.

  [263 Pages Report] The global infectious disease diagnostics market size is projected to reach USD 39.8 billion by 2026 from USD 28.1 billion in 2021, at a CAGR of 7.2%.

  This study involved four major activities in estimating the current size of the infectious disease diagnostics market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research.

  Market Dynamics

  • Global prevalence of infectious diseases and onset of COVID-19
  • Rising focus on R&D and funding in infectious disease diagnostics
  • Growing awareness for early disease diagnosis in developing countries
  • Rising technological advancements in infectious disease diagnostics
  • Shift in focus from centralized laboratories to decentralized POC testing

  COVID-19 Impact on Global Infectious Disease Diagnostics Market

  COVID-19 is an infectious disease caused by the most recently discovered novel coronavirus. Largely unknown before the outbreak began in Wuhan (CHINA) in December 2019, COVID-19 moved from a regional crisis to a global pandemic in just a matter of a few weeks. The COVID-19 pandemic negatively affected the overall sales of most of the companies but had an positive impact on the infectious disease diagnostics market because of the use of infectious disease diagnostic methods for COVID-19 testing. Lockdowns resulting from the COVID-19 pandemic caused people to delay undergoing health checkups, thus affecting the number of tests being performed and sales of reagents.

  Download PDF Brochure @  https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=116764589

  Based on product & service, the infectious disease diagnostics market is segmented into reagents, kits, and consumables; instruments; and software & services. In 2020, the reagents, kits, and consumables segment accounted for the largest share of this market. The frequent purchase of these products due to their recurrent usage drives the market growth of this segment.

  The infectious disease diagnostics market is segmented into immunodiagnostics, polymerase chain reaction (PCR), clinical microbiology, isothermal nucleic acid amplification technology (INAAT), DNA sequencing & NGS, DNA microarrays, and other technologies. In 2020, the immunodiagnostics segment accounted for the largest share. This can be attributed to the increasing use of immunoassays in COVID-19 testing, POC infectious disease testing, the development of novel immunodiagnostic tests, and the rising trend of automation.

  The geographical regions mapped in the report are:1. North America2. Europe3. Asia-Pacific4. Latin America5. Middle East & Africa

  The global infectious disease diagnostics market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America accounted for the largest share of the global infectious disease diagnostics market. The North American infectious disease diagnostics market’s growth can be attributed to the highly developed healthcare system in the US and Canada, the presence of many leading national clinical laboratories, and the easy accessibility to technologically advanced instruments.

  Request for sample pages @  https://www.marketsandmarkets.com/requestsampleNew.asp?id=116764589

  Some key players mentioned in the research report are:

  • Abbott Laboratories (US)
  • Roche Diagnostics Ltd. (Switzerland)
  • bioMérieux SA (France)
  • Thermo Fisher Scientific Inc. (US)
  • Danaher Corporation (US)

This market research study involved the extensive use of secondary sources, directories, and databases to identify and collect information useful for this technical, market-oriented, and financial study of the global biologics safety testing market.

[185 Pages Report] The global biologics safety testing market is projected to reach USD 6.2 billion by 2026 from USD 3.4 billion in 2021, at a CAGR of 12.4% during the forecast period.

The growth of the global biologics safety testing market is driven by factors such as the growth in the biologics and biosimilars markets, growing concerns over cell culture contamination, and rising biopharmaceuticals R&D activities and investments. In addition, emerging markets and increasing biopharmaceutical outsourcing are expected to provide significant growth opportunities for players in the Biologics safety testing market.

Market Dynamics

• Growth in the biosimilars and biologics markets
• Growing concerns over cell culture contamination
• Rising biopharmaceuticals R&D activities and investments
• Emerging markets offer lucrative opportunities
• Increasing biopharmaceutical outsourcing

Many companies are investing heavily in the development of biologics and biosimilars. Currently, more than half of the drug candidates in the discovery stage are biologics, such as proteins, peptides, and monoclonal antibodies. Biologics are expected to contribute around half of the revenue generated by the top 100 pharmaceutical products in the coming years.

Download PDF Brochure @  https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=34624144

Based on application, the biologics safety testing market is segmented into monoclonal antibodies manufacturing, vaccines manufacturing, blood and blood products manufacturing, cellular and gene therapy products manufacturing, and other applications. In 2020, the monoclonal antibodies manufacturing segment accounted for the largest market share. The large share of this segment can be attributed to the rising prevalence of diseases and increasing government initiatives for the development of monoclonal antibody drugs.

The geographical regions mapped in the report are:

North America accounted for the largest share of the biologics safety testing market in 2020. Rapid growth in the biopharmaceutical industry is the major factor driving the growth of the North American biologics safety testing market. Growing academic and government investments, rising demand for high-quality research tools for data reproducibility, increasing awareness among consumers about product safety, and the presence of major market players in this region are also driving the market for biologics safety testing in North America.

Growth of the market is mainly driven by the increasing use of medical imaging modalities due to the rising incidence of chronic diseases, increasing concerns over radiation dose exposure, growth in the installed base of radiology equipment, and growing awareness on radiation dose management.

[226 Pages Report] The global radiation dose management market size is projected to reach USD 423 million by 2025 from USD 220.22 million in 2020, at a CAGR of 13.9% during the forecast period.

The major factors that are expected to be driving the pharmacy automation market are the growing need to minimize medication errors, rapid decentralization of pharmacies, rising geriatric population and rising labor cost. On the other hand, reluctance among the healthcare organizations to adopt pharmacy automation systems is expected to restrain the overall market growth to a certain extent during the forecast period.

Download PDF Brochure @  https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=82326344  

Market Dynamics

• Increasing use of medical imaging modalities due to the growing burden of chronic diseases
• Growing concerns over radiation exposure
• Growing installation base of radiology equipment
• Growing awareness about radiation dose management

COVID -19 IMPACT ON THE RADIATION DOSE MANAGEMENT MARKET

Several countries across the globe have seen non-urgent diagnostic imaging surgeries being postponed due to the pandemic. These procedures utilize additional resources and increase the risk of complications; depending on the procedure, they also increase the chance of needing equipment, resources, or materials such as hospital beds and PPE.

Based on product & service, the radiation dose management market is segmented into radiation dose management solutions and radiation dose management services. The radiation dose management solutions segment is projected to witness the highest growth during the forecast period. The increasing adoption of radiation dose management solutions by healthcare providers owing to the growing regulations regarding ionizing radiation across the globe is the major factor supporting the growth of this segment.

Some key players mentioned in the research report are:

Bayer AG (Germany), GE Healthcare (US), PACSHealth, LLC (US), Sectra Medical Systems (Sweden), Philips Healthcare (Netherlands), Fujifilm Holdings Corporation (Japan), Novarad Corporation (US), Siemens Healthineers (Germany), Agfa HealthCare (Belgium), Canon (Japan), and Qaelum N.V. (Belgium)are the major players in the global radiation dose management market.

Request for sample pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=82326344

The study involved four major activities in estimating the current size of the global non-invasive prenatal testing market. Exhaustive secondary research was done to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing values with industry experts across the value chain through primary research.

[144 Pages Report] The global non-invasive prenatal testing (NIPT) market is estimated to reach USD 7.3 billion by 2024 from USD 3.9 billion in 2019, at a CAGR of 13.5% during the forecast period.

Growth in this market is driven by the high risk of chromosomal abnormalities with increasing maternal age, growing preference for non-invasive techniques over invasive methods, improving reimbursement scenario for NIPT, and increasing awareness of NIPT. However, a dearth of skilled professionals is restraining the growth of this market.

Market Dynamics

• High Risk of Chromosomal Abnormalities With Increasing Maternal Age
• Growing Preference for Noninvasive Techniques Over Invasive Methods
• Improving Reimbursement Scenario for NIPT
• Programs Focusing on Increasing the Awareness of NIPT

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=145607690  

By method, the NIPT products market is segmented into ultrasound detection, biochemical screening tests, and cell-free DNA in maternal plasma tests. The cfDNA in maternal plasma tests segment is expected to grow at the highest CAGR during the forecast period. The high growth of this segment is attributed to technological advancements and increasing company initiatives to develop new products.

The geographical regions mapped in the report are:

• North America
• US
• Canada
• Europe
• Germany
• France
• UK
• Rest of Europe (RoE)
• Asia
• Rest of the World (RoW)

Geographically, the non-invasive prenatal testing market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). In 2019, North America accounted for the largest market share, followed by Europe. On the other hand, Asia is expected to grow at the highest CAGR during the forecast period.

Request for sample pages @   https://www.marketsandmarkets.com/requestsampleNew.asp?id=145607690 

Some key players mentioned in the research report are:

The NIPT market is diversified and highly competitive, with a large number of players competing for market space. The prominent players in the market are Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), GE Healthcare (US), BGI (CHINA), Agilent Technologies, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), PerkinElmer Inc. (US), Laboratory Corporation of America Holdings (US), Natera, Inc. (US), and Yourgene Health (UK)

In the current regulatory climate-where the focus on sustainable techniques has risen — it is expected that the benefits of cold plasma will ensure its greater adoption in the years to come. Innovations in textile production and growing food safety concerns are the major factors driving the growth of this market.

The global cold plasma market size is projected to reach USD 3.4 billion by 2025 from USD 1.6 billion in 2020, at a CAGR of 16.0%. Cold Plasma Market by Industry (Textile, Electronics & Semiconductors, Polymer & Plastic, Food & Agriculture, Medical, Others), Application (Adhesion, Etching, Wound Healing), Regime (Atmospheric, Low pressure), COVID-19 Impact — Global Forecast to 2025

Covid-19 Impact On The Cold Plasma Market

The cold plasma market is expected to be significantly impacted by the Covid-19 pandemic in 2020–2021. However, there could be possible disruptions in the industries such as textile, electronics & semiconductors, polymer & plastic, food & agriculture, and medical during the period of lockdown and movement restrictions imposed globally to control the virus spread and flatten the curve. Social distancing protocols and quarantine measures have reduced the demand for textiles, apparels, semiconductors & electronic appliances, large scale farming practices, and the non essential services has been put off till the post lockdown period.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=187065928

Challenge: Limited Commercialization Of Cold Plasma

Currently, only a number of small nascent players are operating in the cold plasma market. As a result, this technology has witnessed limited commercialization in the last decade. The successful applications of cold plasma have been limited to a few sectors. It is also not easily available due to the low number of production units for cold plasma-related products globally. A lack of awareness of cold plasma has also served to inhibit the greater adoption of this technology.

Benefits Of Cold Plasma Technology

Cold plasma technology has diverse applications in several industries. This processing method possessesmany advantages, such as low water and energy consumption, minimal fiber damage, reduced flammability, low chemical consumption, improved wettability, low cost, and a worker-friendly nature. Also, cold plasma technologies do not require onsite storage of supply chemicals or large volumes of processing water, either for implementation or in post-treatment rinsing.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=187065928

Region Covered in Cold Plasma Market

The cold plasma market in the APAC is expected to grow at the highest CAGR during the forecast period. The Asia Pacific region witnessed the highest growth, which is driven by the continuous shift of electronic manufacturing to Asian countries, increasing demand for decontaminated frozen food, growing manufacturing facilities of textiles, and the rising production of polymers.

Leading Companies

The prominent players in the global cold plasma market are Apyx Medical Corporation (US), Nordson Corporation (US), Adtec Plasma Technology Co. Ltd (Japan), P2i (UK), Relyon Plasma GmbH (Germany), Henniker Plasma (UK), Enercon Industries (US), AcXys Plasma Technologies (France), Plasmatreat (Germany), Tantec A/S (Denmark), Europlasma (Belgium), Thierry Corporation (Germany), Surfx Technologies, LLC (US), SOFTAL Corona & Plasma (Germany), Coating Plasma Innovation (France)

The global glycomics market is estimated to grow from USD 1.0 billion in 2020 to USD 2.0 billion by 2025, at a CAGR of 13.8%.

This study involved four major activities in estimating the current size of the glycomics market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research.

Market Dynamics

• Increasing R&D Expenditure and Funding for Proteomics and Glycomics Research
• Growth of the Proteomics Market
• Technological Advancements in Glycomics Instrumentation

The market is categorized into five product segments, namely, enzymes, instruments, kits, carbohydrates, and reagents & chemicals. The enzymes segment is expected to dominate the market in 2020 and is projected to grow at the highest CAGR during the forecast period. The large share and high growth of this segment can be attributed to the consumable nature of enzymes and their wide applications in a variety of R&D and drug discovery procedures.

Download PDF Brochure@  https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=132685525

Based on application, the glycomics market is segmented into drug discovery & development, disease diagnostics, and other applications. Drug discovery & development is the largest and the fastest-growing application segment in the market, majorly due to the increasing R&D investments in pharmaceutical and biotechnology companies and the growing number of drug discovery research activities in academic research institutes.

The geographical regions mapped in the report are:1. North America2. Europe3. Asia-Pacific4. RoW5. Middle East & Africa

The global glycomics market is segmented into North America (US and Canada), Europe (Germany, the UK, France, Italy, Spain, and the Rest of Europe), Asia Pacific (Japan, China, India, Australia, and the Rest of Asia Pacific), and the Rest of the World (Latin America and the Middle East and Africa). In 2020, North America is expected to dominate the global market, followed by Europe. The largest share of North America is mainly attributed to increasing investments in glycomics research, rising R&D investments in pharmaceutical companies for drug discovery and the presence of all key players.

Request Sample Pages @  https://www.marketsandmarkets.com/requestsampleNew.asp?id=132685525

Some key players mentioned in the research report are:

The prominent players operating in the glycomics market include Merck KGaA (Germany), Agilent Technologies (US), Thermo Fisher Scientific (US), New England Biolabs (US), Shimadzu Corporation (Japan), Takara Bio (Japan), S-BIO (subsidiary of Sumitomo Bakelite Co. Ltd., Japan), Waters Corporation (US), Asparia Glycomics S.L. (Spain), Bio-Techne (US), Bruker Corporation (US), Danaher Corporation (US), RayBiotech (US), Z Biotech (US), Chemily Glycoscience (US), Dextra Laboratories (UK), Lectenz Bio (US), and Ludger Ltd. (UK)

In the past decade, the demand for various health diagnostic tests has increased significantly across the globe. Currently, the market is mainly driven by growing awareness about various health-related disorders, rising incidence of chronic and lifestyle disorders, and the high prevalence of infectious diseases such as HIV and hepatitis in women across the globe.

[270 Pages Report] The women’s health diagnostics market is projected to reach USD 36.6 billion by 2025 from USD 25.0 billion in 2020, at a CAGR of 7.9% during the forecast period.

Market Dynamics

• High prevalence of infectious diseases in women
• Rising incidence of chronic and lifestyle-related disorders in women
• Increasing awareness about fertility testing in women and initiatives by government and health organizations
• Increased adoption of POC and rapid diagnostic tests
• Growth in the number of private diagnostic and imaging centers
• Public-private partnerships are expected to enhance infrastructure in diagnostic imaging centers

Based on application, the women’s health diagnostics market is divided into nine segments—osteoporosis testing, OVC testing, cervical cancer testing, breast cancer testing, pregnancy & fertility testing, prenatal genetic screening & carrier testing, infectious disease testing, STD testing, and ultrasound tests. The breast cancer testing segment accounted for the larger market share in 2019.

Download PDF Brochure @   https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=128928901 

COVID-19 Impact on Global Women’s Health Diagnostics Market

Since the beginning of 2020, more and more countries across the globe shut down their borders and limited transportation and travel to contain the coronavirus (COVID-19) outbreak, thus, creating impediments for international trade and transportation. This had disrupted the supply chains for the women’s health diagnostics market, temporarily leading to fall in demand due to uncertainty in the global economy and capital markets.

The geographical regions mapped in the report are:

1. North America2. Europe3. Asia-Pacific4. Rest of the World (RoW)5. Latin America6. Middle East & Africa

Lack of skilled IT professionals and data security concerns are expected to restrain the growth of the market to a certain extent. In addition, lack of data management and interoperability issues pose as major challenges for the market. On the basis of region, this market is categorized into North America, Europe, Asia-Pacific, and the Rest of the World (RoW).

Request for sample pages @   https://www.marketsandmarkets.com/requestsampleNew.asp?id=128928901  

The Inspection machines market is projected to reach USD 871 million by 2025 from USD 671 million in 2020, at a CAGR of 5.4% during the forecast period.

The growth of this market is majorly driven as companies are now increasingly adopting inspection systems throughout their production lines due to the growing concerns to the regulatory mandates introduced by the government and regulatory bodies in the healthcare industry to maintain compliance with Good Manufacturing Practices (GMP).

Market Dynamics

• Growing number of regulatory mandates to maintain compliance with GMP in the healthcare industry
• Increasing pharmaceutical & biotechnology R&D expenditure
• Growing product recalls
• The increasing number of inspection checkpoints throughout the production line
• Growth in the medical devices industry

The increasing adoption of automated inspection systems in the pharmaceutical and biotechnology industries, growth in the number of product recalls, an increasing number of inspection checkpoints throughout the production line, and technological advancements in inspection systems support the growth of the market.

Download PDF Brochure @  https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=81453085

COVID-19 Impact on Global Inspection Machines Market

Since the beginning of 2020, the majority of the countries worldwide shut down their borders and limited transportation in a bid to contain the coronavirus (COVID-19) outbreak, thus, creating impediments for international trade and transportation. This had disrupted the supply chains for the inspection machines market, temporarily leading to a fall in demand due to uncertainty in the global economy and capital markets.

Additionally, we are estimating that the major share of the medical devices industry that includes imaging devices, dental care devices, and surgical products, among others, contributes to 60-75% of the overall medical devices market. This will have a stagnant or deep fall in the growth rate in 2020 and in a couple of quarters from 2021. A new, USD 5-7 billion market opportunity (by 2021) is opening up in the medical devices industry, including critical care medical devices. On the other hand, the impact of the pandemic on the pharmaceutical industry has been positive, with a steady increase in the manufacturing of nasal drug delivery technologies and the increasing focus on developing a vaccine

COVID-19 Impact on Global Inspection Machines Market

Since the beginning of 2020, the majority of the countries worldwide shut down their borders and limited transportation in a bid to contain the coronavirus (COVID-19) outbreak, thus, creating impediments for international trade and transportation. This had disrupted the supply chains for the inspection machines market, temporarily leading to a fall in demand due to uncertainty in the global economy and capital markets.

In 2019, North America accounted for the largest share of the inspection machines market, followed by Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The large share of this market segment can be attributed to the significant growth opportunities for players operating in the inspection machines market owing to the presence of a large number of pharmaceutical and biotechnology companies & medical device manufacturers in the region, stringent regulatory mandates for healthcare manufacturers, an increasing number of inspection checkpoints in the production line, and highly regulated inspection standards & obligatory compliance in the region.

Request for sample pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=81453085

Growth in this market is driven majorly by the rising R&D spending in the pharmaceutical & biopharmaceutical industry, growing demand for membrane filtration technology, increasing purity requirements in end-user segments, and growing focus on developing large-molecule biopharmaceuticals. However, the high cost of systems is expected to restrain the growth of the lab filtration market to a certain extent during the forecast period.

What the Market Looks Like?

MarketsandMarkets forecasts the global laboratory filtration market is projected to reach USD 5.3 billion by 2026 from USD 3.6 billion in 2021, at a CAGR of 7.8% from 2021 to 2026. The global laboratory filtration market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. 

HCS is used in several stages of the drug discovery process, including primary and secondary screening, target identification and validation and toxicity studies. As HCS instruments are expensive, they add to the overall drug development expense for pharmaceutical and biopharmaceutical companies.

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=12936082

What are Key Trends in the Market?

The growth of the laboratory filtration market is primarily influenced by the following factors:

• Rising R&D spending in pharmaceutical & biotechnology industries
• Growing demand for membrane filtration
• Increasing purity requirements in end-user segments
• Increasing focus on developing large-molecule biopharmaceuticals

In pharmaceutical filtration, the newly developed nanofiber coating technology offers greater flexibility, control, and durability as compared to the traditional process of electrospinning. This new coating is made of fibers typically ranging from 0.3 to 0.5 microns in size, which can be increased to up to 1 micron. The fiber diameter distribution and layer thickness can easily be changed according to application requirements. 

Read more about laboratory filtration market @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=12936082

[159 Pages Report] The North American nuclear medicine market is expected to reach USD 2.7 billion by 2024 from an estimated USD 2.2 billion in 2019, growing at a CAGR of 4.1% during the forecast period.

The study involved four major activities in estimating the current size for the North American nuclear medicine market. Exhaustive secondary research was done to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size.

Market Dynamics

• Increasing Incidence and Prevalence of Target Conditions
• Alpha Radioimmunotherapy-Based Targeted Cancer Treatment
• Initiatives to Lessen the Demand-Supply Gap of Mo-99

The increasing adoption of automated inspection systems in the pharmaceutical and biotechnology industries, growth in the number of product recalls, an increasing number of inspection checkpoints throughout the production line, and technological advancements in inspection systems support the growth of the market.

Download PDF Brochure@   https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1108 

Based on type, the market is categorized into diagnostic and therapeutic nuclear medicine. The therapeutic nuclear medicine segment is further segmented into alpha emitters, beta emitters, and brachytherapy isotopes.

The geographical regions mapped in the report are:

1. North America

2. US

3. Canada

Geographically, the North American market comprises of US and Canada. In 2018, the US accounted for the largest share of the nuclear medicine market. The large share can be attributed to the development of novel technologies for radioisotope production, government funding, and company initiatives in the country.

Based on application, the North American nuclear medicine market is segmented into SPECT, PET, and therapeutic applications. The SPECT applications segment is further segmented into cardiology, bone scans, thyroid applications, pulmonary scans, and other SPECT applications. The thyroid applications segment is projected to register the highest growth rate in the forecast period. The high growth of this segment can be attributed to the increasing incidence and prevalence of thyroid disorders.

Request for sample pages @  https://www.marketsandmarkets.com/requestsampleNew.asp?id=1108 

The study involved four major activities in estimating the current size of the HLA typing for the transplants market. Exhaustive secondary research was conducted to collect information on the market and its different subsegments.

According to the new market research report “ HLA Typing for Transplant Market by Technology (PCR (SSO, SSP, Real Time), Sequencing (NGS, Sanger)), Product (Instrument, Reagent, Software), Application (Chimerism, Antibody Screening), End User (Hospital, Diagnolab, Academia) – Global Forecast to 2025“, published by MarketsandMarkets™, HLA typing for the transplants market is expected to reach USD 968 million by 2025 from USD 656 million in 2019, at a CAGR of 6.7%.

Key Factors Driving Market Growth:

The demand for transplant diagnostic products is expected to grow mainly due to factors such as the increasing public-private funding for target research activities, the growing burden of infectious diseases, the growing number of transplant procedures, and technological advancements in the field of transplant diagnostics.

Revenue Growth Analysis:

The HLA typing for the transplants market is expected to reach USD 968 million by 2025 from USD 656 million in 2019, at a CAGR of 6.7%

Download PDF Brochure:   https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=96374742

Don’t miss out on business opportunities in HLA typing for transplants market

The HLA typing for transplants market comprises several stakeholders such as original equipment manufacturers (OEMs), product distributors and channel partners, hospitals and transplant centers, emergency care units and trauma centers, diagnostic laboratories, contract manufacturers and third-party suppliers, research laboratories and academic institutes, clinical research organizations (CROS), government and non-governmental regulatory authorities, and market research and consulting firms. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information.

Browse in-depth TOC on “HLA Typing for Transplant Market”

141 – Tables36 – Figures193 – Pages

The HLA typing for the transplants market, by technology, is segmented into molecular and non-molecular assay technologies. In 2019, the molecular assay technologies segment accounted for the largest share of the HLA typing for the transplants market. The large share of this segment can be attributed to the benefits offered by molecular assays such as low turnaround time, high procedural efficacy, the study of multiple samples, and real-time sample analysis.

Request Sample Report:  https://www.marketsandmarkets.com/requestsampleNew.asp?id=96374742

According to the new market research report ” US Anticoagulation Therapy Market by Product ((Anticoagulants Drugs (NOACs, Warfarin)), PT/INR Devices (In-Office, Home Testing)), Service Type (Testing & Consulting), Type of Clinic (Hospital Associated, Independent & Pharmacy-based)”, published by MarketsandMarkets™ , US anticoagulation therapy market is projected to reach USD 27.83 Billion by 2022 from USD 17.25 Billion in 2016, at a CAGR of 8.5%.

The market is segmented into products (anticoagulation drugs and PT/INR testing devices) and anticoagulation clinics. The growth in the anticoagulation drugs market is primarily driven by the rising incidence of venous thromboembolism, atrial fibrillation, and stroke; long-term administration and high volume of recurring sales of anticoagulation drugs; and increasing demand for novel oral anticoagulants (NOACs).

Expected Revenue Growth:

[86 Pages Report] The US anticoagulation therapy market is projected to reach USD 27.83 Billion by 2022 from USD 17.25 Billion in 2016, at a CAGR of 8.5%.

Accessories to Fuel the Growth of US Anticoagulation Therapy Market :

In this report, the US anticoagulation therapy market is segmented on the basis of products and clinics. On the basis of products, the market is segmented into anticoagulation drugs and PT/INR testing devices.

Browse in-depth TOC on “US Anticoagulation Therapy Market”

29 – Tables

25 – Figures

86 – Pages

Download PDF Brochure:   https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=114158575  

Based on drug type, the anticoagulation therapy market for drugs is segmented into NOACs, warfarin (VKA), and other drugs. In 2016, the NOACs segment dominated the US anticoagulation therapy market for drugs. Due to the better safety and efficacy of NOACs as compared to traditional therapies, the adoption of NOACs is higher as compared to traditional drugs. In addition, key market players such as Portola Pharmaceuticals (received FDA approval for its NOAC Betrixaban in July 2017) are focusing on the development of NOACs in order to capitalize on the growth opportunities presented by this shift in market dynamics

The anticoagulation therapy market for PT/INR testing devices is segmented into in-office testing devices and home testing devices. The in-office devices segment dominated the US anticoagulation therapy market for PT/INR testing devices. The large share of this segment is mainly attributed to the large number of patients opting for in-office testing services.

Request Sample Report:   https://www.marketsandmarkets.com/requestsampleNew.asp?id=114158575  

C. H. Boehringer Sohn (Germany), Bristol-Myers Squibb (US), Johnson & Johnson (US), Pfizer (US), Daiichi Sankyo (Japan), and Portola Pharmaceuticals (US) are the major market players in the global market for drugs while Roche (Switzerland), Abbott (US), Siemens (Germany), Alere (US), and CoaguSense (US) are the major market players in the US anticoagulation therapy market for PT/INR home testing devices.